Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Other Non Operating Income (2024 - 2026)

Maze Therapeutics' Other Non Operating Income history spans 3 years, with the latest figure at $2.3 million for Q1 2026.

  • On a quarterly basis, Other Non Operating Income fell 10.33% to $2.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.3 million, a 260.51% increase, with the full-year FY2024 number at -$8.8 million, changed N/A from a year prior.
  • Other Non Operating Income hit $2.3 million in Q1 2026 for Maze Therapeutics, down from $2.6 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for MAZE hit a ceiling of $2.6 million in Q1 2025 and a floor of -$4.8 million in Q1 2024.
  • Historically, Other Non Operating Income has averaged -$646166.7 across 3 years, with a median of -$714000.0 in 2024.
  • Biggest five-year swings in Other Non Operating Income: soared 154.93% in 2025 and later decreased 10.33% in 2026.
  • Tracing MAZE's Other Non Operating Income over 3 years: stood at -$1.6 million in 2024, then skyrocketed by 259.06% to $2.6 million in 2025, then fell by 10.33% to $2.3 million in 2026.
  • Business Quant data shows Other Non Operating Income for MAZE at $2.3 million in Q1 2026, $2.6 million in Q1 2025, and -$1.6 million in Q4 2024.